|
Post by rvc on Dec 6, 2015 17:29:52 GMT -5
BTW, I was responding to Slugworth 008's post. I still haven't quite figured out the nuances of this message board.
|
|
|
Post by mssciguy on Dec 6, 2015 17:35:13 GMT -5
If it looks like a duck and quacks like a duck, it's a duck. As you correctly point out, SNY has not made one positive statement about Afrezza, not ONE! Certainly both SNY and Mann understand that just one statement that SNY is supportive of Afreza would cause the stock price to explode to the side. But nothing, just the sound of crickets. Many longs are of the opinion(and hope) that SNY is purposely sandbagging Afrezza because of some ulterior motive, like acquiring Afrezza, or maybe even MNKD, on the cheap. Sorry, but I can't by the conspiracy theories. Again, if it looks like a duck and quacks like a duck, it's a duck. Like it or not(I don't because I've lost a lot of money on this stock) it seems clear that the current management team at SNY just isn't into Afrezza, and I expect them to unload it at the earliest opportunity. I might have bought your argument just a little before seeing an ad for an inhaled particle asthma medication at the gym today. FACT -- current particle technology allows tailor made particles which act just like gases. This is huge, and MNKD did it with human insulin, one of the most difficult candidates possible. But you are right, Brandicourt looks like a Keystone Kop at this point. Not to say it's not just a stealthy approach. Look at the clinical trials sites for the EU and the US. MNKD has pushed the frontiers of demonstrated safety and adaptability to notoriously difficult molecules. Sanofi with there huge portfolio would be completely negligent not tapping into more TS for vaccines, oncology, peptides, etc. With regards to losing money, what did you lose it on? Options? Stock? Warrants?
|
|